S. Rajkumar
Hematology · 2002–2022
A researcher in the Science corpus: 31 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hematology — 196 citations into it
- Molecular Biology — 126 citations into it
- Oncology — 125 citations into it
- Genetics — 29 citations into it
Whom S. Rajkumar trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Rajkumar overall
Papers from S. Rajkumar's perspective
Ordered by how strongly the researchers S. Rajkumar trusts endorse each paper. Same corpus, a different order for every researcher.
- An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. (Archives of Internal Medicine)
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (American journal of hematology/oncology)
- International uniform response criteria for multiple myeloma (Leukemia)
- International staging system for multiple myeloma. (Journal of Clinical Oncology)
- Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. (Mayo Clinic proceedings)
- Small Cell Lung Cancer (Recent Results in Cancer Research)
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG… (The Lancet)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (New England Journal of Medicine)
- Clinical and biologic implications of recurrent genomic aberrations in myeloma. (Blood)
- N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients (Circulation)
Their papers
- Clonal competition with alternating dominance in multiple myeloma. (2012) — 648 citations
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) — 2,697 citations
- Proteasome inhibition as a novel therapeutic target in human cancer. (2005) — 597 citations
- Improved survival in multiple myeloma and the impact of novel therapies. (2008) — 2,308 citations
- International uniform response criteria for multiple myeloma (2006) — 2,475 citations
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. (2005) — 682 citations
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005) — 674 citations
- Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. (2007) — 858 citations
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) — 4,253 citations
- Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. (2004) — 885 citations
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) — 1,343 citations
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022) — 694 citations
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022) — 3,276 citations
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020) — 699 citations
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) — 2,558 citations
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial (2016) — 771 citations
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. (2015) — 1,221 citations
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) — 731 citations
- Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012) — 992 citations
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) — 821 citations